224 related articles for article (PubMed ID: 19125002)
1. Chemosensitivity and chemoresistance testing in ovarian cancer.
Cree IA
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
Kurbacher CM; Cree IA
Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
[TBL] [Abstract][Full Text] [Related]
7. [Cancer-associated gene abnormalities and chemosensitivity].
Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804
[TBL] [Abstract][Full Text] [Related]
8. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.
Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE
Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382
[TBL] [Abstract][Full Text] [Related]
10. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
11. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
Ng TY; Ngan HY; Cheng DK; Wong LC
Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
[TBL] [Abstract][Full Text] [Related]
12. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
13. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
[TBL] [Abstract][Full Text] [Related]
14. [Result of individualized chemotherapy with a newly developed in vitro chemosensitivity testing in ovarian cancer].
Iijima N; Sekiya S; Tokita H; Oosaki T; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Oct; 43(10):1323-8. PubMed ID: 1955784
[TBL] [Abstract][Full Text] [Related]
15. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
Ness RB; Wisniewski SR; Eng H; Christopherson W
Anticancer Res; 2002; 22(2B):1145-9. PubMed ID: 12168915
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of ornithine decarboxylase as a measure of chemosensitivity testing.
Bachrach U
Methods Mol Med; 2005; 110():197-211. PubMed ID: 15901937
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
Gerçel-Taylor C; Ackermann MA; Taylor DD
Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
[TBL] [Abstract][Full Text] [Related]
18. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
Gazzaniga P; Gradilone A; de Berardinis E; Sciarra A; Cristini C; Naso G; di Silverio F; Frati L; Aglianò AM
BJU Int; 2009 Jul; 104(2):184-8. PubMed ID: 19154503
[TBL] [Abstract][Full Text] [Related]
19. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
[TBL] [Abstract][Full Text] [Related]
20. Consolidation therapy in ovarian cancer: where do we stand?
Dearnley DD; McMeekin DS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
